EIC Accelerator

Iktos is a French company specializing in artificial intelligence-driven solutions for medicinal chemistry and new drug discovery. It offers SaaS platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, accelerating pharmaceutical R&D. Iktos also develops AI-driven synthesis automation platform Iktos Robotics and has its own drug pipeline targeting oncology and autoimmune diseases.

Esencia Foods develops a unique mycelium-based fermentation platform to produce plant-based meat alternatives. Their products offer distinctive textures, clean labels, and competitive pricing.

Vivalyx operates a patented organ preservation system designed to enhance the success of organ transplantation. Its technology combines static cold storage with machine perfusion, offering a blood-free alternative that aims to increase the vitality and availability of donor organs, thereby improving patient outcomes.

Vivalyx operates a patented organ preservation system designed to enhance the success of organ transplantation. Its technology combines static cold storage with machine perfusion, offering a blood-free alternative that aims to increase the vitality and availability of donor organs, thereby improving patient outcomes.

Novobiom is a company focused on bioremediation, specifically designed to address persistent and pervasive pollutants in contaminated soil. Utilizing innovative mycoremediation technology, which employs mushrooms, Novobiom offers tailored solutions for soil pollution, effectively treating hazardous waste while promoting sustainability. In addition to its remediation services, the company provides consultation to enhance sustainability awareness and innovation, guiding industries in achieving their strategic environmental goals through biomimetic approaches.

BioThrust develops customized gassing solutions for bioreactors.

PFx Biotech is a pioneering company that specializes in the development of alternative proteins using precision fermentation. They focus on producing human milk proteins, which are nourishing and contain beneficial bioactivities such as immune-boosting, anti-microbial, and anti-viral properties. By leveraging their fermentation platform, they aim to provide sustainable protein alternatives that can help reduce water consumption and greenhouse gas emissions, thereby promoting a more environmentally friendly and animal-free protein landscape.

Novobiom is a company focused on bioremediation, specifically designed to address persistent and pervasive pollutants in contaminated soil. Utilizing innovative mycoremediation technology, which employs mushrooms, Novobiom offers tailored solutions for soil pollution, effectively treating hazardous waste while promoting sustainability. In addition to its remediation services, the company provides consultation to enhance sustainability awareness and innovation, guiding industries in achieving their strategic environmental goals through biomimetic approaches.

Premium Fertility develops an assisted reproductive technology for embryo transfer, featuring a direct embryo transfer system that integrates optical, microfluidic, and automated components to enable clinicians to place embryos with greater precision and consistency while addressing uncertainties in attachment.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

BioThrust develops customized gassing solutions for bioreactors.

MyoPax develops advanced regenerative therapies using stem cells to address debilitating muscle illnesses.

Sparxell develops innovative, biodegradable pigments derived from cellulose material. These dye-free pigments mimic the natural colors found in birds and butterflies, offering a low-carbon alternative to traditional materials for various industries such as fashion, cosmetics, paint, and packaging.

MyoPax develops advanced regenerative therapies using stem cells to address debilitating muscle illnesses.

Premium Fertility develops an assisted reproductive technology for embryo transfer, featuring a direct embryo transfer system that integrates optical, microfluidic, and automated components to enable clinicians to place embryos with greater precision and consistency while addressing uncertainties in attachment.

Invitris is a biotech company focused on developing protein-based drugs and manufacturing bacteriophages to combat antibiotic-resistant bacteria. The company specializes in synthesizing arbitrary phages within a single system, which allows for effective quality assessment, synthetic phage production, and quality control services. By enabling personalized diagnostics, Invitris aims to provide patients with targeted treatments for bacterial infections, ensuring both safety and practical application in the fight against resistant pathogens.

PFx Biotech is a pioneering company that specializes in the development of alternative proteins using precision fermentation. They focus on producing human milk proteins, which are nourishing and contain beneficial bioactivities such as immune-boosting, anti-microbial, and anti-viral properties. By leveraging their fermentation platform, they aim to provide sustainable protein alternatives that can help reduce water consumption and greenhouse gas emissions, thereby promoting a more environmentally friendly and animal-free protein landscape.

Captor Therapeutics is a bio-pharmaceutical firm focused on development of protein degradation drugs for cancer and autoimmune diseases. Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called "undruggable proteome".

NanoPhoria is a biotechnology company focused on cardiovascular therapies. It develops non-viral, nanoparticle-based drug delivery platforms designed to target the heart directly and improve the delivery of biologics, including peptides and RNAs. The company is pursuing tissue-directed delivery methods and inhalable formulations, with preclinical programs aimed at treating cardiovascular diseases such as heart failure with reduced ejection fraction. Its platform enables selective organ- and cell-level targeting to expand administration routes beyond traditional systemic delivery, supporting research and development to advance cardiovascular health.

Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

Veridi Technologies develops innovative technology that enables farmers to detect plant diseases and pathogens at early stages. By leveraging computer vision and automated microscopy, the company optimizes laboratory diagnostics that are accurate, affordable, and scalable. This advanced approach not only facilitates the early identification of diseases but also helps analyze soil biodiversity. As a result, farmers can reduce their reliance on pesticides while improving crop yields, contributing to more sustainable agricultural practices.

Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.

Invitris is a biotech company focused on developing protein-based drugs and manufacturing bacteriophages to combat antibiotic-resistant bacteria. The company specializes in synthesizing arbitrary phages within a single system, which allows for effective quality assessment, synthetic phage production, and quality control services. By enabling personalized diagnostics, Invitris aims to provide patients with targeted treatments for bacterial infections, ensuring both safety and practical application in the fight against resistant pathogens.

NanoPhoria is a biotechnology company focused on cardiovascular therapies. It develops non-viral, nanoparticle-based drug delivery platforms designed to target the heart directly and improve the delivery of biologics, including peptides and RNAs. The company is pursuing tissue-directed delivery methods and inhalable formulations, with preclinical programs aimed at treating cardiovascular diseases such as heart failure with reduced ejection fraction. Its platform enables selective organ- and cell-level targeting to expand administration routes beyond traditional systemic delivery, supporting research and development to advance cardiovascular health.

Founded in 2022, Holloid specializes in real-time, image-based monitoring of colloidal objects in industrial processes. Its platform enables continuous tracking and analysis of physical characteristics, motion, and interactions, benefiting food, pharma, and energy sectors by reducing costs, improving quality, and enhancing safety through data-driven insights.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

PFx Biotech is a pioneering company that specializes in the development of alternative proteins using precision fermentation. They focus on producing human milk proteins, which are nourishing and contain beneficial bioactivities such as immune-boosting, anti-microbial, and anti-viral properties. By leveraging their fermentation platform, they aim to provide sustainable protein alternatives that can help reduce water consumption and greenhouse gas emissions, thereby promoting a more environmentally friendly and animal-free protein landscape.

PFx Biotech is a pioneering company that specializes in the development of alternative proteins using precision fermentation. They focus on producing human milk proteins, which are nourishing and contain beneficial bioactivities such as immune-boosting, anti-microbial, and anti-viral properties. By leveraging their fermentation platform, they aim to provide sustainable protein alternatives that can help reduce water consumption and greenhouse gas emissions, thereby promoting a more environmentally friendly and animal-free protein landscape.

InSpek develops biological and chemical monitoring systems using integrated photonics. The company aims to democratize access to chemical analysis thanks to integrated optics. Its sensors make the most of micro and nano-optical chip technologies to maximize light-matter interactions and improve chemical detection.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

Solmeyea is a biotechnology company specializing in producing single-cell proteins from CO2 at scale. These proteins serve as carbon-negative ingredients for various food applications. The company also explores producing biomaterials and commodities from CO2, aiming to contribute to CO2 circularity. Solmeyea collaborates with corporations emitting high levels of CO2, transforming their emissions into valuable products to address climate change and food insecurity.

Onego Bio is a biotechnology company focused on producing animal-free egg white protein through precision fermentation. Their flagship product, Bioalbumen, offers a sustainable alternative to traditional egg proteins, boasting identical taste and nutritional profiles while providing superior functional properties and a significantly reduced environmental footprint. By employing commercially proven technology, Onego Bio meets the growing demand for stable and sustainable functional ingredients within the food industry. The company has gained recognition as a leader in innovation, winning Fast Company’s 2023 World Changing Ideas award. Additionally, Onego Bio is actively involved in the industry as a co-founder of the Precision Fermentation Alliance and Food Fermentation Europe, further establishing its commitment to advancing sustainable food solutions.

SpacePharma SA is a Swiss company established in 2012, specializing in providing microgravity services and solutions for research. Based in Delémont, the company offers an innovative miniaturized laboratory system called mGnify, which can be remotely controlled and utilized across various microgravity platforms, including ground simulators, parabolic flights, and nano satellites. By facilitating access to microgravity environments, SpacePharma enables researchers to conduct advanced studies in areas such as bio-chemistry, drug screening, gene expression, protein crystallization, and the pathogenicity of bacteria. The company assists clients throughout all phases of their experiments, employing cutting-edge technology to deliver unique data and accelerate research and development processes.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Melt&Marble is a company focused on enabling the plant-based food industry by providing innovative fat solutions that are both environmentally friendly and palatable. Utilizing precision fermentation, Melt&Marble produces animal fats without the use of animals by engineering microbial metabolism. This approach allows the company to control the structure and properties of the fats generated, enabling the creation of fats that can closely mimic traditional animal fats or even develop entirely new formulations. By generating yeast cell factories through advanced bioengineering techniques, Melt&Marble empowers food manufacturers to enhance the taste and health profile of plant-based foods, aiming to make them as appealing and nutritious as their animal-based counterparts.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

SpacePharma SA is a Swiss company established in 2012, specializing in providing microgravity services and solutions for research. Based in Delémont, the company offers an innovative miniaturized laboratory system called mGnify, which can be remotely controlled and utilized across various microgravity platforms, including ground simulators, parabolic flights, and nano satellites. By facilitating access to microgravity environments, SpacePharma enables researchers to conduct advanced studies in areas such as bio-chemistry, drug screening, gene expression, protein crystallization, and the pathogenicity of bacteria. The company assists clients throughout all phases of their experiments, employing cutting-edge technology to deliver unique data and accelerate research and development processes.

InSpek develops biological and chemical monitoring systems using integrated photonics. The company aims to democratize access to chemical analysis thanks to integrated optics. Its sensors make the most of micro and nano-optical chip technologies to maximize light-matter interactions and improve chemical detection.

JaxBio develops AI-driven diagnostic technology for cancer, using AI-based chips for genetic and epigenetic profiling and array-based cancer tests to enable a simple, sensitive blood test for cancer detection and monitoring. Its technology identifies biomarker sets that distinguish cancer types and subtypes across stages, supporting early detection, disease monitoring, and prediction of treatment response.

Vaxdyn is a biotechnology company focused on the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. Utilizing innovative technology, Vaxdyn's vaccines incorporate antigens, immunomodulators, nanoparticles, and monoclonal antibodies to effectively combat bacterial infections. This approach helps healthcare professionals mitigate the public health impact of infections that are resistant to traditional treatments. The company actively engages with its customers through various communication channels, including phone, email, and online applications, to address inquiries related to their vaccine offerings.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Diamante is a company based in Verona, Italy, that specializes in the development and manufacturing of diagnostic devices for autoimmune diseases, utilizing innovative nanomaterials. Founded in 2016, the company leverages plants as bioreactors to produce nanoparticles derived from modified plant viruses. This approach allows Diamante to create advanced tools for diagnosing and potentially treating autoimmune conditions, focusing on sustainable and efficient production methods. Through its research and development efforts, Diamante aims to contribute significantly to the field of autoimmune disease therapy.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

AltraTech designs biosensors and semiconductor chips for DNA testing to support food traceability in the agriculture sector. Incorporated in 2013 and based in Shannon, Ireland, the company also develops a portable viral detection device that combines enrichment and semiconductor techniques to match the sensitivity and specificity of PCR in a compact form, enabling rapid and accurate measurement of viral DNA, RNA, antigens, or antibodies for diagnostics.

Solmeyea is a biotechnology company specializing in producing single-cell proteins from CO2 at scale. These proteins serve as carbon-negative ingredients for various food applications. The company also explores producing biomaterials and commodities from CO2, aiming to contribute to CO2 circularity. Solmeyea collaborates with corporations emitting high levels of CO2, transforming their emissions into valuable products to address climate change and food insecurity.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Diamante is a company based in Verona, Italy, that specializes in the development and manufacturing of diagnostic devices for autoimmune diseases, utilizing innovative nanomaterials. Founded in 2016, the company leverages plants as bioreactors to produce nanoparticles derived from modified plant viruses. This approach allows Diamante to create advanced tools for diagnosing and potentially treating autoimmune conditions, focusing on sustainable and efficient production methods. Through its research and development efforts, Diamante aims to contribute significantly to the field of autoimmune disease therapy.

SpacePharma SA is a Swiss company established in 2012, specializing in providing microgravity services and solutions for research. Based in Delémont, the company offers an innovative miniaturized laboratory system called mGnify, which can be remotely controlled and utilized across various microgravity platforms, including ground simulators, parabolic flights, and nano satellites. By facilitating access to microgravity environments, SpacePharma enables researchers to conduct advanced studies in areas such as bio-chemistry, drug screening, gene expression, protein crystallization, and the pathogenicity of bacteria. The company assists clients throughout all phases of their experiments, employing cutting-edge technology to deliver unique data and accelerate research and development processes.

Melt&Marble is a company focused on enabling the plant-based food industry by providing innovative fat solutions that are both environmentally friendly and palatable. Utilizing precision fermentation, Melt&Marble produces animal fats without the use of animals by engineering microbial metabolism. This approach allows the company to control the structure and properties of the fats generated, enabling the creation of fats that can closely mimic traditional animal fats or even develop entirely new formulations. By generating yeast cell factories through advanced bioengineering techniques, Melt&Marble empowers food manufacturers to enhance the taste and health profile of plant-based foods, aiming to make them as appealing and nutritious as their animal-based counterparts.

Vaxdyn is a biotechnology company focused on the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. Utilizing innovative technology, Vaxdyn's vaccines incorporate antigens, immunomodulators, nanoparticles, and monoclonal antibodies to effectively combat bacterial infections. This approach helps healthcare professionals mitigate the public health impact of infections that are resistant to traditional treatments. The company actively engages with its customers through various communication channels, including phone, email, and online applications, to address inquiries related to their vaccine offerings.

Omini develops a portable, multiplex biosensor platform for blood testing that enables the simultaneous detection of multiple biomarkers. The device is designed for chronic disease monitoring and therapy management, providing personalized biomarker data to adjust treatments and help prevent acute crises, with applications for general practitioners. Incorporated in 2019 and based in Saint-Mandé, France, Omini aims to offer a low-cost, regular monitoring solution that supports routine assessment of complex conditions such as heart failure.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

AltraTech designs biosensors and semiconductor chips for DNA testing to support food traceability in the agriculture sector. Incorporated in 2013 and based in Shannon, Ireland, the company also develops a portable viral detection device that combines enrichment and semiconductor techniques to match the sensitivity and specificity of PCR in a compact form, enabling rapid and accurate measurement of viral DNA, RNA, antigens, or antibodies for diagnostics.

Omini develops a portable, multiplex biosensor platform for blood testing that enables the simultaneous detection of multiple biomarkers. The device is designed for chronic disease monitoring and therapy management, providing personalized biomarker data to adjust treatments and help prevent acute crises, with applications for general practitioners. Incorporated in 2019 and based in Saint-Mandé, France, Omini aims to offer a low-cost, regular monitoring solution that supports routine assessment of complex conditions such as heart failure.

SpacePharma SA is a Swiss company established in 2012, specializing in providing microgravity services and solutions for research. Based in Delémont, the company offers an innovative miniaturized laboratory system called mGnify, which can be remotely controlled and utilized across various microgravity platforms, including ground simulators, parabolic flights, and nano satellites. By facilitating access to microgravity environments, SpacePharma enables researchers to conduct advanced studies in areas such as bio-chemistry, drug screening, gene expression, protein crystallization, and the pathogenicity of bacteria. The company assists clients throughout all phases of their experiments, employing cutting-edge technology to deliver unique data and accelerate research and development processes.

Iris.ai offers an AI-powered science assistant designed for R&D departments. It enhances research efficiency through smart search, filters, summaries, and autonomous extraction of scientific insights.

neuroClues develops AI-driven eye-tracking technology for clinical use that quantifies neurological function during exams. The platform provides an easy-to-use eye-tracking environment enabling clinicians to assess brain health non-invasively and monitor neurological conditions. By applying AI to eye movement data, the company aims to enable earlier detection of neurological disorders such as Parkinson's and Alzheimer's disease, potentially improving patient outcomes and informing treatment decisions. The approach offers a non-invasive diagnostic aid that can complement traditional assessments and support streamlined clinical workflows.

Scope Biosciences develops molecular diagnostics leveraging CRISPR-Cas technology. It originated as a spin-off from Wageningen University & Research. The company aims to provide actionable nucleic acid detection in healthcare and agriculture with high specificity for single-nucleotide differences and sensitivity to trace genetic material, packaged in a format that can be used outside traditional laboratory settings to support on-site decision making by clinicians and agricultural professionals.

Gedea Biotech develops an antibiotic-free treatment for vaginal fungal infections using its substance GA101. This natural substance lowers pH, provides physical barrier protection, and inhibits biofilm formation. The company's first product is a topical treatment for vaginal fungal infections.

Qlucore is a prominent provider of advanced bioinformatics software designed for research and precision diagnostics in the life sciences. Founded in 2007 by researchers from Lund University in Sweden, the company aims to simplify the analysis of complex data generated in the fields of genetics and proteomics. Its flagship product, Qlucore Omics Explorer, is a user-friendly bioinformatics tool that enables researchers, technicians, and physicians to easily interpret and visualize large datasets. Additionally, Qlucore offers Qlucore Diagnostics, an AI-powered platform for multi-omics companion and precision diagnostics that integrates with various data-generating instruments. With a global presence, Qlucore serves customers in approximately 35 countries, including leading pharmaceutical companies, hospitals, and academic institutions.

BetaGlue Technologies SpA is a Milan-based company that specializes in the development and manufacture of medical devices designed for loco-regional radiation therapy targeting unresectable solid tumors. The company's innovative product features a proprietary beta-emitting biocompatible matrix, which facilitates the controlled administration of radionuclides directly into tumor masses. This technology not only enhances the effectiveness of cancer treatment but also plays a crucial role in preventing complications that can arise following procedures such as lung and liver biopsies. By focusing on localized therapies, BetaGlue Technologies aims to improve patient outcomes and advance the field of cancer treatment.

KLISBio is a pioneering company in regenerative medicine that utilizes silk as a versatile and biocompatible scaffold material to advance tissue regeneration methods. The company focuses on various clinical applications within the orthopedic and vascular markets, developing innovative silk-based biomaterials that facilitate the regeneration of human tissues. These materials are designed to degrade safely within the body, making them suitable for medical research and treatment of tissue-related diseases. By harnessing the potential of nano-fibers, KLISBio aims to transform the landscape of medical technology and improve patient outcomes.

HAWK Biosystems develops a companion diagnostics platform designed to quantify protein-protein interactions and their post-translational modifications in single-cell and fixed tissue samples. This platform offers built-in specificity while preserving the morphological integrity and cellular heterogeneity of tissues, enabling more precise treatment decisions in cancer, inflammation, and immune disorders.

O11 Biomedical GmbH is a spin-off from RWTH Aachen University's Institute for Applied Medical Engineering, specifically the Department of Biohybrids & Medical Textiles. The company specializes in liquid breathing technology aimed at treating hypercapnia, a condition characterized by elevated carbon dioxide levels in the blood. O11 Biomedical's innovative technology effectively binds carbon dioxide from intestinal fluid, facilitating its excretion through natural processes. By doing so, the company seeks to enhance both the survival and quality of life for patients afflicted with this respiratory condition.

AptaTargets is a biopharmaceutical company developing therapeutic applications based on aptamer technology. The company advances drug candidates from preclinical stages toward clinical development with the aim of reaching phase 2 trials. Its approach uses aptamers to recognize specific therapeutic targets, offering an antibody-like mechanism with potential advantages in precision and safety. The pipeline addresses inflammatory and neuroprotective indications, including conditions such as ischemic stroke, myocardial infarction, and autoimmune diseases, and seeks to modulate disease pathways through targeted molecular recognition.

Founded in 2017, Nectin Therapeutics develops novel monoclonal antibodies targeting the Nectin family of receptors and ligands. These antibodies aim to treat solid and hematological malignancies by modulating immune checkpoint mechanisms.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective and safe options for managing chronic pain and hearing loss. Through its research and development efforts, Hoba Therapeutics seeks to deliver disease-modifying treatments that enhance the quality of life for patients suffering from neuropathic pain.

Toopi Organics is a biotechnology company based in Langon, France, established in 2019. It develops microbiological and agricultural technologies to transform human urine into fertilizers and biostimulants for agriculture. The company collects and upcycles human urine, depollutes and enriches it with microorganisms to provide natural, economical, and efficient alternatives to chemical fertilizers. Its products include Arbop and Vitip, which support plant growth and crop health, offering farming communities an environmentally conscious option for nutrient supply.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

Brevel develops innovative cultivation technology for sustainable, low-cost production of microalgae. Its high-tech, indoor, automated systems use internal illumination to achieve over 90% cost reduction and up to 200 times higher yields compared to traditional methods. Brevel targets various markets where microalgae-derived products are in demand.

X-trodes develops scalable wireless electronic technology and analytics for biopotential signals, enabling advanced electrophysiological monitoring. Its solution combines wearable hardware with automated, high-resolution analysis to support clinical evaluation and treatment across brain, eye, muscle, and heart signals. The technology is designed to track physiological activity during sleep and everyday tasks, providing objective measurements that can inform medical decisions and help improve patients’ quality of life. By integrating sensors and analytics in a cohesive platform, X-trodes aims to make continuous biopotential monitoring practical in routine healthcare settings, offering clinicians and patients insights into neural, ocular, muscular, and cardiovascular health through a single, scalable system.

X-trodes develops scalable wireless electronic technology and analytics for biopotential signals, enabling advanced electrophysiological monitoring. Its solution combines wearable hardware with automated, high-resolution analysis to support clinical evaluation and treatment across brain, eye, muscle, and heart signals. The technology is designed to track physiological activity during sleep and everyday tasks, providing objective measurements that can inform medical decisions and help improve patients’ quality of life. By integrating sensors and analytics in a cohesive platform, X-trodes aims to make continuous biopotential monitoring practical in routine healthcare settings, offering clinicians and patients insights into neural, ocular, muscular, and cardiovascular health through a single, scalable system.

Picterus is developing an app to diagnose jaundice in newborns, aiming to reduce the global infant mortality associated with this condition. The platform uses a patented color calibration card and smartphone camera for accurate image capture, providing healthcare professionals and caregivers with a reliable tool for early detection and timely intervention.

Celtic Biotech is a biotechnology company focused on developing innovative therapies for the treatment of solid cancers and pain in humans. Co-founded by John Reid, the company utilizes specialized receptor-binding proteins derived from snake venom to create its therapeutic products. These novel candidate therapies aim to enhance patient survival rates, improve quality of life, and reduce the overall costs of cancer treatment. By leveraging unique biological mechanisms, Celtic Biotech addresses significant medical challenges in oncology and pain management.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

GeneCode AS creates new disease-modifying pharmaceuticals.

GeneCode AS creates new disease-modifying pharmaceuticals.

Genewity B.V. is a biotech company that works closely with LUmc to build on the achievements of our scientific and business teams in cell and gene therapies.

Hooke Bio Ltd. is a biotechnology company based in Shannon, Ireland, focused on developing microfluidic technologies for drug screening and related applications. Founded in 2014, the company has created a fully integrated high-throughput screening system that utilizes 3D microtissues, such as spheroids and organoids, to generate biological data. This innovative, patent-protected technology aims to reduce reliance on animal models in preclinical studies and accelerate the drug development process. By enabling pharmaceutical companies and clinicians to develop more accurate disease models and optimize treatments based on individual patient samples, Hooke Bio enhances the ability to test and repurpose drugs effectively, ultimately improving patient care and outcomes.

BioSimulytics is a company that specializes in creating AI-powered software tailored for drug researchers in the pharmaceutical industry. Its innovative platform integrates molecular chemistry, quantum physics, and advanced artificial intelligence to enhance the drug development process. By focusing on crystal-structure prediction, BioSimulytics enables researchers to accurately predict stable polymorphs, which significantly improves the speed, certainty, and quality of product data. This technology aims to streamline the development of pharmaceuticals, ultimately supporting researchers in their quest to bring new drugs to market more efficiently.

Molecular Attraction is a research and development firm focused on creating innovative solutions for vector-borne disease control and eradication. The company specializes in identifying biological compounds that can influence the behavior of various vector organisms, including mosquitoes, ticks, flies, and rodents. By utilizing sustainable technology and chemical blends, Molecular Attraction aims to provide effective, long-lasting, and low-maintenance pest control solutions. Their approach is designed to enhance the efficacy of vector-borne disease management while prioritizing environmental sustainability and cost-effectiveness within the pest control industry.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Xenothera is a biotechnology company that specializes in xenotherapy, focusing on the development of innovative immunological treatments. Utilizing a unique technological platform, Xenothera combines expertise in animal genetics with advanced immunology processes to create new therapeutic approaches for various medical conditions, including immunomodulation and infectious diseases. The company is particularly noted for its development of hyperimmune polyclonal sera, which represents a new generation of passive immunotherapy. By controlling the entire process—from the selection of immunogens to the purification of immunoglobulins—Xenothera is able to accelerate the development and market authorization of its therapies, thereby facilitating timely access to novel treatments for patients.

Nimble Diagnostics is a company that offers a range of DNA testing services, including paternity testing, prenatal gender testing, family relationship testing, ancestry DNA testing, and DNA art. In addition to these services, the company provides cancer nutraceuticals, aiming to support patients' health and well-being. Nimble Diagnostics leverages the internet to deliver its offerings globally at affordable prices, maintaining a commitment to accessible molecular diagnostics. The company also focuses on developing medical monitoring devices that enhance patient care, particularly for individuals with medical implants. These devices enable continuous, non-invasive monitoring, allowing healthcare providers to transition from reactive to proactive care, thereby reducing clinical complications associated with implanted stents.

Zymofix facilitates sustainable and circular agriculture by developing creative, effective, and commercially feasible microbial products that reduce farmers' reliance on agrochemicals while maintaining high productivity.

ReST Therapeutics is a clinical biotechnology company focused on developing innovative therapies for complex central nervous system (CNS) disorders. Utilizing its patented medication candidate, the company aims to create treatments that selectively target NMDA receptors, with the intention of addressing conditions such as post-traumatic stress disorder (PTSD) and Alzheimer's disease. By advancing its candidate through non-clinical testing, ReST Therapeutics seeks to improve the efficacy of cognitive preservation and provide protection against neurotoxicity, thereby enhancing therapeutic outcomes for patients suffering from these debilitating neural disorders.

Founded in 2017, SolasCure is a biotechnology company based in Wales, UK. It specializes in developing innovative hydrogel treatments for patients with chronic wounds. Its flagship product, Aurase, facilitates wound debridement, removing dead or infected tissue to enhance healing.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

ChainCraft is a company focused on mixed culture fermentation technology aimed at producing sustainable bio-based chemicals for the chemical, food, and feed industries. Their innovative approach utilizes waste mitigation services to convert low-grade organic residues, such as food waste, agricultural byproducts, and the organic fraction of municipal solid waste, into high-value fatty acids. By transforming biobased organic waste streams into valuable chemical building blocks, ChainCraft offers a competitive alternative to traditional industry-produced chemicals, promoting environmental sustainability and resource efficiency in the chemical industry.

MultiplexDX develops accurate, specific, quantifiable diagnostic tests combining molecular biology and histopathological methods. Based in Kosice, Slovakia and Gaithersburg, Maryland, USA, it aims to improve cancer diagnosis and treatment.

MaxiVAX is a Swiss clinical-stage biotechnology company developing personalized cancer immunotherapies. Its lead product, MVX-ONCO-1, is an advanced therapeutic product for various tumors, currently in phase I trials.